Blurbs

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Biophytis (BPTS) and Neurosense Therapeutics Ltd. (NRSN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRXResearch Report), Biophytis (BPTSResearch Report) and Neurosense Therapeutics Ltd. (NRSNResearch Report) with bullish sentiments.

Pacira Pharmaceuticals (PCRX)

In a report released today, Serge Belanger from Needham maintained a Buy rating on Pacira Pharmaceuticals, with a price target of $76.00. The company’s shares closed last Wednesday at $51.47.

According to TipRanks.com, Belanger is a 4-star analyst with an average return of 6.5% and a 46.9% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pacira Pharmaceuticals with a $81.71 average price target.

See today’s best-performing stocks on TipRanks >>

Biophytis (BPTS)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biophytis, with a price target of $15.00. The company’s shares closed last Wednesday at $1.03, close to its 52-week low of $0.81.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -21.1% and a 27.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Biophytis has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.

Neurosense Therapeutics Ltd. (NRSN)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Neurosense Therapeutics Ltd., with a price target of $7.00. The company’s shares closed last Wednesday at $1.95, close to its 52-week low of $1.23.

According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -34.2% and a 15.4% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Processa Pharmaceuticals, and Virpax Pharmaceuticals.

Currently, the analyst consensus on Neurosense Therapeutics Ltd. is a Moderate Buy with an average price target of $7.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PCRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos